Best Agrolife Limited promoters have confirmed that no shares were encumbered during the Financial Year 2025-2026. The disclosure, submitted to the stock exchanges, confirms compliance with Regulation 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This confirmation ensures that the promoters and persons acting in concert have not created any direct or indirect encumbrance on their holdings beyond those previously disclosed.

The filing was made by Vimal Kumar, Promoter & Managing Director, on behalf of the promoters and promoter group of Best Agrolife . The declaration covers the period of the Financial Year 2025-2026 and was addressed to BSE Limited and the National Stock Exchange of India Limited. The document confirms that the promoter group has maintained the status of its shareholding without additional liens or charges.

The disclosure identifies the individuals covered under the promoter and promoter group category. The table below lists the names and their respective classifications as per the regulatory filing.

The confirmation was signed on April 04, 2026, in New Delhi. A copy of the disclosure was also forwarded to the Audit Committee of Best Agrolife Limited for their records. The filing provides transparency regarding the holding structure of the company's key stakeholders during the specified financial year.

Best Agrolife Limited reported a significant decline in financial performance for the financial year ended March 31, 2026, with annual net profit falling 87% to ₹9 crore from ₹70 crore in the previous year. Revenue from operations dropped 31% to ₹1,257 crore compared to ₹1,814 crore in FY25. The company posted a net loss of ₹37 crore in Q4 FY26, compared to a net loss of ₹22 crore in Q4 FY25, while quarterly revenue stood at ₹156 crore, sharply lower than ₹274 crore recorded in the corresponding period last year. The Board of Directors recommended a final dividend of ₹0.10 per equity share for FY26.

Management Commentary and Strategic Outlook

Mr. Vimal Kumar, Managing Director, attributed the Q4 performance to a sharp increase in raw material prices due to the Gulf conflict. The company strategically curtailed sales in March across B2B and B2C segments to avoid lower realization sales, impacting potential revenues of approximately ₹50–70 crore. To mitigate rising input costs, the company implemented two rounds of price increases in early April and May 2026. Despite the challenges, the company reduced OPEX by 15% year-on-year to ₹280 crore and decreased inventory levels from ₹773 crore in FY25 to ₹651 crore as of March 31, 2026.

Operational Highlights

During FY26, the company expanded its specialty portfolio with the launch of three patented formulations: Bestman™, Fetagen™, and Shot Down™. It strengthened its intellectual property with the grant of seven patents, including a patented Nano Urea. The company plans to launch four additional patented products in FY27: Fluzam™, Midcotin™, Cubax Power Extra™, and Trishanku™. Branded sales accounted for 63% of total sales in FY26, with patented products contributing 41% to branded sales.

Financial Performance

The following table summarises the key financial metrics for the quarter and year:

Board Decisions and Auditor's Report

The Board of Directors, in its meeting held on May 27, 2026, approved the audited financial results and recommended a final dividend of ₹0.10 per equity share for FY26. M/s Walker Chandiok & Co LLP, Statutory Auditor, issued an un-modified opinion but included an emphasis of matter regarding a search operation by the Income Tax Department in September 2023 and a subsequent demand order for ₹0.95 crore for assessment year 2021-22.